Ramesh A. Shivdasani, MD, PhD (Damon Runyon Scholar ‘98-‘99) of Dana-Farber Cancer Institute, Boston, and colleagues discovered a mechanism for how cancer cells become resistant to cetuximab/Erbitux, which is used to treat colorectal cancer or squamous cell cancer of the head and neck. They reported that a protein called ERBB2 allows cells to remain unresponsive to the drug. The study suggests that combining cetuximab with ERBB2-inhibiting drugs could be an effective therapy to both heighten and/or restore the drug’s potency. These findings were published in the journal Science Translational Medicine.